The Center for Drug Evaluation (CDE) of China has granted clinical study approval for Multitude Therapeutics Inc.’s proprietary injectable drug candidate, AMT-676, as indicated on the CDE website. The drug is intended for the treatment of solid tumors.
AMT-676 is an antibody-drug conjugate (ADC) that targets CDH17, a gene situated on chromosome 8q22.1 and predominantly expressed in embryonic and adult intestinal epithelial cells, as well as certain pancreatic ductal epithelial cells. CDH17 is notably not expressed in the liver cells, esophageal epithelial cells, and gastric mucosa of healthy individuals. However, it is variably expressed across a spectrum of cancers including gastric, colorectal, liver, esophageal, pancreatic, and bile duct cancers. The elevated expression levels of CDH17 are considered to be significantly correlated with patient prognosis and risk assessment.
Currently, a dozen drugs targeting the CDH17 antigen are in development, encompassing a range of therapeutic modalities such as monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and cell therapies.- Flcube.com
